Botulinum toxin in clinical practice

被引:273
|
作者
Jankovic, J
机构
[1] Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA
来源
关键词
D O I
10.1136/jnnp.2003.034702
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Botulinum toxin, the most potent biological toxin, has become a powerful therapeutic tool for a growing number of clinical applications. This review draws attention to new findings about the mechanism of action of botulinum toxin and briefly reviews some of its most frequent uses, focusing on evidence based data. Double blind, placebo controlled studies, as well as open label clinical trials, provide evidence that, when appropriate targets and doses are selected, botulinum toxin temporarily ameliorates disorders associated with excessive muscle contraction or autonomic dysfunction. When injected not more often than every three months, the risk of blocking antibodies is slight. Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications.
引用
收藏
页码:951 / 957
页数:7
相关论文
共 50 条
  • [41] Botulinum Toxin A in Clinical Practice, the Technical Aspects and What Urologists Want to Know about It
    van Breda, Hendrikje M. K.
    Heesakkers, John P. F. A.
    UROLOGIA INTERNATIONALIS, 2015, 95 (04) : 411 - 416
  • [42] Clinical use of non-A botulinum toxins: Botulinum toxin type C and botulinum toxin type F
    Eleopra, Roberto
    Tugnoli, Valeria
    Quatrale, Rocco
    Rossetto, Ornella
    Montecucco, Cesare
    Dressler, Dirk
    NEUROTOXICITY RESEARCH, 2006, 9 (2-3) : 127 - 131
  • [43] The effect of botulinum toxin A on pain associated with cervical dystonia (CD) in routine clinical practice
    Trosch, R.
    Misra, V.
    Maisonobe, P.
    Om, S.
    MOVEMENT DISORDERS, 2020, 35 : S46 - S47
  • [44] Botulinum toxin type-A practice in bruxism cases
    Bolayir, Giray
    Bolayir, Ertugrul
    Coskun, Akin
    Oezdemir, Ali Kemal
    Topaktas, Suat
    NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH, 2005, 12 (01) : 43 - 46
  • [45] Botulinum Toxin for the Treatment of Raynaud's Conditions of the Hand: Clinical Practice Updates and Future Directions
    O'Donohoe, Patrick
    Mcdonnell, Jake
    Wormald, Justin
    Aljohmani, Lylas
    Cronin, Kevin
    Durcan, Laura
    Kennedy, Oran
    Dolan, Roisin
    TOXINS, 2024, 16 (11)
  • [46] Assessment of Botulinum Toxin Aesthetic Outcomes Clinical Study vs Real-World Practice
    Glogau, Richard
    Biesman, Brian
    Kane, Michael
    JAMA DERMATOLOGY, 2015, 151 (11) : 1177 - 1178
  • [47] Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres
    Bakheit, AMO
    EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (04) : 415 - 419
  • [48] Botulinum Toxin and the Treatment of Headache: A Clinical Review
    Finkel, Alan G.
    HEADACHE, 2011, 51 (10): : 1565 - 1572
  • [49] Clinical trials of botulinum toxin in the treatment of spasticity
    Simpson, DM
    MUSCLE & NERVE, 1997, : S169 - S175
  • [50] Botulinum toxin mechanism of action and clinical applications
    Naumann, M
    MEDIZINISCHE WELT, 1998, 49 (08): : 388 - 391